Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
- Status
- COMPLETED
- Phase
- PHASE1
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
- Status
- COMPLETED
- Phase
- PHASE1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Status
- TERMINATED
- Phase
- PHASE2
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3